ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,408.90
0.36%
S&P ASX All Technology
3,893.00
0.20%
Brent Oil
77.625
0.00%
US Dollar vs AUD
1.58353
0.00%
Bitcoin
105,078.96
0.33%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Keros Therapeutics Inc (KROS) Share Price

Keros Therapeutics Inc

Keros Therapeutics Inc (KROS)

NASDAQ
11.84
-0.18
(-1.50%)
Closed 26 January 8:00AM
Delayed by 15 minutes
11.76
-0.08
(-0.68%)
After Hours: 10:47AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
11.76
Bid
11.75
Offer
12.05
Volume
1,493,425
11.82 Day's Range 12.56
9.775 52 Week Range 73.00
Market Cap
476.367M
Previous Close
12.02
Open
12.04
Last Trade
2
@
11.75
Last Trade Time
Financial Volume
US$ 18,125,507
VWAP
12.1369
Average Volume (3m)
1,487,987
Shares Outstanding
40,507,409
Dividend Yield
-
PE Ratio
-3.13
Earnings Per Share (EPS)
-3.78
Revenue
151k
Net Profit
-152.99M

About Keros Therapeutics Inc

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candida... Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.kerostx.com
Headquarters
Dover, Delaware, USA
Founded
-
Keros Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KROS. The last closing price for Keros Therapeutics was US$12.02. Over the last year, Keros Therapeutics shares have traded in a share price range of US$ 9.775 to US$ 73.00.

Keros Therapeutics currently has 40,507,409 shares in issue. The market capitalisation of Keros Therapeutics is US$486.90 million. Keros Therapeutics has a price to earnings ratio (PE ratio) of -3.13.

Ask ADVFN Intelligence (AI)

KROS Latest News

More News

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

25 January 2025
Edgar (US Regulatory)

Form 8-K - Current report

22 January 2025
Edgar (US Regulatory)

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...

22 January 2025
GlobeNewswire Inc.

Form 8-K - Current report

15 January 2025
Edgar (US Regulatory)

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...

15 January 2025
GlobeNewswire Inc.

Form 8-K - Current report

11 January 2025
Edgar (US Regulatory)

Form 8-K - Current report

12 December 2024
Edgar (US Regulatory)

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

12 December 2024
GlobeNewswire Inc.

Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1...

10 December 2024
GlobeNewswire Inc.

Form 8-K - Current report

03 December 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.7636.9382558879710.99712.0510.74276633011.20615535CS
4-4.88-29.326923076916.6417.259.775231207811.98927857CS
12-46.74-79.897435897458.572.379.775148798722.2882174CS
26-38.54-76.6202783350.372.379.77583773829.37977175CS
52-44.52-79.104477611956.28739.77559681237.22674729CS
156-33.65-74.102620568245.41739.77535032139.12508599CS
260-8.34-41.492537313420.188.89.77527118041.49292029CS

KROS - Frequently Asked Questions (FAQ)

What is the current Keros Therapeutics share price?
The current share price of Keros Therapeutics is US$ 11.76
How many Keros Therapeutics shares are in issue?
Keros Therapeutics has 40,507,409 shares in issue
What is the market cap of Keros Therapeutics?
The market capitalisation of Keros Therapeutics is USD 486.9M
What is the 1 year trading range for Keros Therapeutics share price?
Keros Therapeutics has traded in the range of US$ 9.775 to US$ 73.00 during the past year
What is the PE ratio of Keros Therapeutics?
The price to earnings ratio of Keros Therapeutics is -3.13
What is the cash to sales ratio of Keros Therapeutics?
The cash to sales ratio of Keros Therapeutics is 3.2k
What is the reporting currency for Keros Therapeutics?
Keros Therapeutics reports financial results in USD
What is the latest annual turnover for Keros Therapeutics?
The latest annual turnover of Keros Therapeutics is USD 151k
What is the latest annual profit for Keros Therapeutics?
The latest annual profit of Keros Therapeutics is USD -152.99M
What is the registered address of Keros Therapeutics?
The registered address for Keros Therapeutics is 850 NEW BURTON ROAD, SUITE 201, DOVER, DELAWARE, 19904
What is the Keros Therapeutics website address?
The website address for Keros Therapeutics is www.kerostx.com
Which industry sector does Keros Therapeutics operate in?
Keros Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
EVAXEvaxion Biotech AS
US$ 5.99
(64.56%)
55.41M
ELABPMGC Holdings Inc
US$ 3.0901
(56.07%)
76.48M
PCLAPicoCELA Inc
US$ 4.60
(49.35%)
3.75M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
GODNUGolden Star Acquisition Corporation
US$ 3.11
(-75.82%)
17.51k
GODNGolden Star Acquisition Corporation
US$ 2.93
(-65.67%)
902.76k
NXTTNext Technology Holding Inc
US$ 1.37
(-54.93%)
2.56M
SGLYSingularity Future Technology Ltd
US$ 1.625
(-38.45%)
917.77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90.11
(-38.07%)
8
ACONAclarion Inc
US$ 0.0557
(28.94%)
811.91M
NVNINVNI Group Ltd
US$ 4.38
(193.96%)
366.98M
RIMEAlgorhythm Holdings Inc
US$ 0.0357
(4.69%)
284.97M
GOEVCanoo Inc
US$ 0.475
(43.94%)
282.22M
NVDANVIDIA Corporation
US$ 142.62
(-3.12%)
232.88M

KROS Discussion

View Posts
TheFinalCD TheFinalCD 2 weeks ago
$KROS halts all dosing in the TROPOS Phase 2 clinical trial of cibotercept (KER-012) based on the ongoing safety review due to new observations of pericardial effusion adverse events

https://x.com/BioStocks/status/1879492237891080688

$KROS the TROPOS trial is being terminated early. The Co continues to expect to present topline data from all treatment arms in this trial in Q2
https://x.com/BioStocks/status/1879493199288586404
👍️0
retireat40 retireat40 1 month ago
Wow. What a turd 
👍️0
retireat40 retireat40 1 month ago
Shocked this is still sub 18
👍️0
Dennis14 Dennis14 1 month ago
Bought in at 18.00
👍️0
Monksdream Monksdream 4 months ago
KROS more upside possible

👍️0
Monksdream Monksdream 11 months ago
KROS new 52=week high
👍️0

Your Recent History

NASDAQ
KROS
Keros Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads